Bayer to present new Kerendia™ (finerenone) data from comprehensive clinical trial program across a broad range of patients with chronic kidney disease and type 2 diabetes

Berlin, June 3, 2022, – Bayer will present new renal and cardiovascular data from the comprehensive Kerendia™ (finerenone) clinical trial program at the 2022 American Diabetes Association (ADA) 82nd Scientific Sessions. This new data will comprise of further insights from FIDELITY, including late-breaking data from a new post-hoc analysis…
Read More

About The Author

Jonathan Jeriah

See author's posts